CA2925421C - Proteines hybrides de l'interleukine-2 et leurs utilisations - Google Patents

Proteines hybrides de l'interleukine-2 et leurs utilisations Download PDF

Info

Publication number
CA2925421C
CA2925421C CA2925421A CA2925421A CA2925421C CA 2925421 C CA2925421 C CA 2925421C CA 2925421 A CA2925421 A CA 2925421A CA 2925421 A CA2925421 A CA 2925421A CA 2925421 C CA2925421 C CA 2925421C
Authority
CA
Canada
Prior art keywords
fusion protein
cell
nucleic acid
acid molecule
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2925421A
Other languages
English (en)
Other versions
CA2925421A1 (fr
Inventor
Fahar Merchant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicenna Therapeutics Inc
Original Assignee
Medicenna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicenna Therapeutics Inc filed Critical Medicenna Therapeutics Inc
Publication of CA2925421A1 publication Critical patent/CA2925421A1/fr
Application granted granted Critical
Publication of CA2925421C publication Critical patent/CA2925421C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

L'invention concerne des protéines hybrides de l'interleukine-2. Plus particulièrement, elle concerne en partie des protéines hybrides comprenant un fragment de protéine de l'interleukine-2 lié à un fragment de protéine membre de la famille Bcl-2.
CA2925421A 2013-09-24 2014-09-24 Proteines hybrides de l'interleukine-2 et leurs utilisations Active CA2925421C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881931P 2013-09-24 2013-09-24
US61/881,931 2013-09-24
PCT/CA2014/050917 WO2015042707A1 (fr) 2013-09-24 2014-09-24 Protéines hybrides de l'interleukine-2 et leurs utilisations

Publications (2)

Publication Number Publication Date
CA2925421A1 CA2925421A1 (fr) 2015-04-02
CA2925421C true CA2925421C (fr) 2023-08-29

Family

ID=52741679

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2925421A Active CA2925421C (fr) 2013-09-24 2014-09-24 Proteines hybrides de l'interleukine-2 et leurs utilisations

Country Status (6)

Country Link
US (3) US10781242B2 (fr)
EP (1) EP3049445A4 (fr)
JP (2) JP2016533167A (fr)
CN (1) CN105722860A (fr)
CA (1) CA2925421C (fr)
WO (1) WO2015042707A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925421C (fr) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Proteines hybrides de l'interleukine-2 et leurs utilisations
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2018118907A1 (fr) 2016-12-21 2018-06-28 Nkmax Co., Ltd. Composition pharmaceutique et procédés comprenant des cellules immunitaires et du ponatinib
BR112019019973A2 (pt) * 2017-03-24 2020-04-28 Orpheus Bioscience Inc pantlds para tratamento de transtornos autoimunes
EP3641814A4 (fr) * 2017-06-19 2021-06-23 Medicenna Therapeutics Inc. Utilisations et procédés pour des superagonistes et agonistes d'il-2 et des fusions de ceux-ci
JP2021519336A (ja) * 2018-03-28 2021-08-10 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｉｌ−２コンジュゲート
EP3806888B1 (fr) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Constructions régulatrices dérivées de pde5 et procédés d'utilisation en immunothérapie
WO2020160047A2 (fr) * 2019-01-28 2020-08-06 Rhode Island Council On Postsecondary Education Fixation d'épitope médiée par un peptide phlip® au niveau de surfaces cellulaires
JP2023515247A (ja) 2020-03-31 2023-04-12 ハンミ ファーマシューティカル カンパニー リミテッド 新規な免疫活性インターロイキン２アナログ
AU2022314797A1 (en) * 2021-07-21 2024-02-22 Trutino Biosciences Inc. Linker polypeptides
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
WO2023170475A2 (fr) * 2022-03-08 2023-09-14 Medicenna Therapeutics, Inc. Utilisations et procédés pour molécules bifonctionnelles de cytokine d'il-2, d'il-13 et d'il-4
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816249A (en) 1981-11-17 1989-03-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
EP0091539B2 (fr) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gène codant pour interleukin-2 polypeptide, ADN recombinant portant ledit gène, lignées cellulaires possédant le recombinant ADN et procédé pour la préparation d'interleukin-2 utilisant lesdites cellules
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5068177A (en) 1983-12-28 1991-11-26 Scripps Clinic And Research Foundation Anti-idiotype antibodies induced by synthetic polypeptides
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4931543A (en) 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US5227159A (en) 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
EP1757694A3 (fr) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Antigene de membrane spécifique à la prostate
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP2829609A1 (fr) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Anticorps CTLA-4 humains et leurs utilisations
AU7756100A (en) 1999-10-08 2001-04-23 Curagen Corporation Interleukin-2 like protein and nucleic acids encoding same
JP4334174B2 (ja) 1999-11-15 2009-09-30 オニックス ファーマシューティカルズ，インコーポレイティド 腫瘍崩壊性アデノウイルス
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
ES2381025T3 (es) 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US6894527B1 (en) 2003-05-12 2005-05-17 Xilinx, Inc. Evolved circuits for bitstream protection
WO2005007121A2 (fr) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Polypeptides de l'interleukine-2(il-2) mutante
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007527242A (ja) * 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP1846020B1 (fr) 2005-01-27 2013-08-21 Novartis Vaccines and Diagnostics, Inc. Procedes pour traiter un carcinome cellulaire renal
EP1866339B8 (fr) 2005-03-25 2021-12-01 GITR, Inc. Molecules de liaison gitr et leurs utilisations
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
AU2006347606B2 (en) * 2005-09-09 2012-10-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cell proliferation
WO2009046104A1 (fr) 2007-10-01 2009-04-09 University Of Miami Arnsi à cible aptamère pour empêcher l'atténuation ou la suppression du fonctionnement de cellule t
EP2057972A1 (fr) 2007-11-07 2009-05-13 N.V. Organon Dépôt intra-utérine
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110171219A1 (en) * 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
US20100183545A1 (en) * 2008-10-14 2010-07-22 The United States Of America, As Represented By The Secretary, Targeted cargo protein combination therapy
SI2376535T1 (sl) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
JP5766124B2 (ja) 2009-01-21 2015-08-19 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
LT2398498T (lt) 2009-02-17 2019-01-10 Ucb Biopharma Sprl Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
ME03447B (fr) 2010-03-04 2020-01-20 Macrogenics Inc Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
US20120213771A1 (en) 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
BR112012026227A2 (pt) 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo
KR101527300B1 (ko) 2010-09-09 2015-06-09 화이자 인코포레이티드 4-1ｂｂ 결합 분자
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
WO2012054929A2 (fr) 2010-10-22 2012-04-26 Protox Therapeutics Corp. Utilisation d'albumine sérique humaine pour diminuer l'immunogénicité de protéines thérapeutiques
JP6093712B2 (ja) * 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
WO2012119093A1 (fr) 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonistes et antagonistes de l'interleukine-2
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2012139112A1 (fr) 2011-04-08 2012-10-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Fusions d'ubiquitine pour améliorer l'efficacité de toxines ciblées à action cytosolique
WO2013006490A2 (fr) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Anticorps se liant spécifiquement à tim3
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
EP2912466B1 (fr) 2012-10-26 2018-08-29 Institut Gustave Roussy Procédés pour prédire la sensibilité d'un sujet à une thérapie avec anticorps activant les cellules t
PT3300745T (pt) 2013-02-15 2019-11-27 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
WO2015042706A1 (fr) * 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Protéines de fusion de liaison au récepteur de l'interleukine-4 et leurs utilisations
CA2925421C (fr) * 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Proteines hybrides de l'interleukine-2 et leurs utilisations
US10711272B2 (en) 2014-01-21 2020-07-14 City Of Hope CTLA-4 aptamer siRNA species
MX2016010128A (es) 2014-02-07 2017-02-02 Univ Mcmaster Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US9873741B2 (en) 2015-03-06 2018-01-23 Sorrento Therapeutics, Inc. Antibody therapeutics that bind TIM3
EP3268037B1 (fr) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Agonistes cd27
EA201890630A1 (ru) 2015-09-01 2018-10-31 Эйдженус Инк. Антитела против pd-1 и способы их применения
EP3387155A4 (fr) 2015-12-10 2019-06-12 Definiens AG Procédés de traitement et de sélection de patients sensibles à l'immunothérapie anticancéreuse
WO2017152088A1 (fr) 2016-03-04 2017-09-08 JN Biosciences, LLC Anticorps anti-tigit

Also Published As

Publication number Publication date
US20240067689A1 (en) 2024-02-29
US20160229901A1 (en) 2016-08-11
US11680090B2 (en) 2023-06-20
JP2016533167A (ja) 2016-10-27
EP3049445A4 (fr) 2017-10-25
WO2015042707A1 (fr) 2015-04-02
JP2020005655A (ja) 2020-01-16
CN105722860A (zh) 2016-06-29
CA2925421A1 (fr) 2015-04-02
US10781242B2 (en) 2020-09-22
EP3049445A1 (fr) 2016-08-03
US20210246183A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
US11680090B2 (en) Interleukin-2 fusion proteins and uses thereof
US11084856B2 (en) Interleukin-4 receptor-binding fusion proteins and uses thereof
Bosiljcic et al. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs
JP2021506849A (ja) 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
US20190070177A1 (en) Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination
JP2006034296A (ja) Ｗｔ１改変ペプチド
KR20220020411A (ko) 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
CN101180315A (zh) Il-21变体
Huynh et al. Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy
JP2022542167A (ja) Ｃ／ＥＢＰアルファｓａＲＮＡを使用する組成物および方法
US20240082377A1 (en) Bacillus calmette-guerin (bcg) and antigen presenting cells for treatment of bladder cancer
Baskar et al. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a potential target antigen for immunotherapy of human B cell chronic lymphocytic leukemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190917

EEER Examination request

Effective date: 20190917

EEER Examination request

Effective date: 20190917

EEER Examination request

Effective date: 20190917

EEER Examination request

Effective date: 20190917

EEER Examination request

Effective date: 20190917

EEER Examination request

Effective date: 20190917